ClinicalTrials.gg
CompletedNCT02370511MITRALUpdated Oct 10, 2023Results posted

Mitral Implantation of TRAnscatheter vaLves

An interventional study of Transcatheter Mitral Valve Replacement in Mitral Valve Disease, sponsored by Mayra Guerrero. Completed at 15 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Mayra Guerrero · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this trial is to establish the safety and feasibility of the Edwards SAPIEN XT™and SAPIEN 3™ device and delivery systems in patients with severe symptomatic calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.

Read the detailed description

Design:

A prospective pilot study enrolling extremely high surgical risk patients with symptomatic severe calcific mitral valve disease undergoing implantation of an Edwards Sapien XT or SAPIEN 3 valve in the mitral position.

There are three arms in this study evaluating three separate patient populations described below:

  • Native Mitral Valve with severe Mitral Annular Calcification (MAC): Patients with symptomatic severe disease of a native mitral valve due to severe mitral annular calcification.
  • Valve-in-Ring: Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis.
  • Valve-in-Valve: Patients with failing bioprosthetic surgical valves with severe regurgitation or stenosis

The delivery approaches include: standard transeptal, modified transeptal approach with a guidewire externalized through a sheath percutaneously placed in the left ventricle, surgical trasnapical and surgical transatrial delivery approach with or without surgical resection of the anterior mitral valve (MV) leaflet (in the native mitral valve arm).

The MITRAL Trial site investigative team (heart team) consists of dedicated representatives from cardiac surgery, interventional cardiology, echocardiology, neurology, study coordination and other multi-disciplinary team members consistent with a transcatheter aortic valve replacement (TAVR) model.

Endpoints

Most endpoints were defined following the Mitral Valve Academic Research Consortium (MVARC) recommendations with minor modifications.73

The primary safety endpoint is: technical success at exit from the cath lab

  • Technical success (at exit from the cath lab) is defined as:
  • Successful vascular and/or TA access, delivery and retrieval of the transcatheter valve delivery system
  • Deployment of a single valve
  • Correct position of transcatheter valve in the mitral annulus
  • Adequate performance of the prosthetic heart valve (mean mitral valve gradient (MVG) \<10 mmHg) without residual mitral regurgitation (MR) grade ≥2 (+)
  • No need for additional surgery or re-intervention (includes drainage of pericardial effusion)
  • The patient leaves the cath lab alive

The primary performance endpoint is: absence of MR grade 2 (+) or greater or mean MVG ≥10 mmHg at 30 days and 1 year.

Secondary safety endpoints include: Procedural success and all -cause mortality at 30 days and 1 year.

  • Procedural Success (30 days) in defined as:

    • Device success at 30 days
    • No device/procedure related severe adverse event (SAE's) including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
  • Device success is defined as:

    • Stroke free survival with original valve in place
    • No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve
    • Proper placement and intended function of the replacement valve, including
    • No migration, fracture, thrombosis, hemolysis or endocarditis
    • No replacement valve stenosis (MV gradient \< 10 mmHg)
    • Replacement valve regurgitation \< 2 + (including central and paravalvular leak) and without associated hemolysis
    • No increase in AI from baseline (more than 1 grade) and LVOT gradient \< 20 mmHg increase from baseline

Additional secondary safety and effectiveness endpoints will be evaluated at two time points: (1) acute, covering events occurring out to 30 days or hospital discharge, whichever is longer; and (2) longer-term, covering events from 31 days to 1 year, and include the following:

Additional Safety Endpoints:

Freedom from

  • all stroke and TIA (MVARC)
  • myocardial infarction
  • major vascular complication (MVARC)
  • life-threatening bleeding (MVARC)
  • mitral valve reoperation or catheter-based intervention for: valve thrombosis, valve displacement, or other valve placed procedure-related complication
  • hemolysis
  • endocarditis
  • moderate or severe central mitral insufficiency ≥ 2 (+), and/or moderate or severe perivalvular leak causing ≥ 2 (+) mitral insufficiency
  • significant mitral stenosis (mean MVG >10 mmHg)
  • new permanent pacemaker insertion
  • new aortic valve dysfunction (difference greater than 1(+) severity compared with baseline)
  • new LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient.
  • acute kidney injury (MVARC)
  • new onset atrial fibrillation
  • blood transfusion
  • access site infection
  • need for iatrogenic ASD closure after index procedure

Additional Effectiveness Endpoints:

  1. Rehospitalization at 1 year and Total days alive and out of hospital (from date of index procedure)
  2. Clinical improvement per NYHA Class (from baseline) by at least 1 class.
  3. Clinical improvement per Quality of Life instruments (>10 points from baseline): (KCCQ 12) (Appendix N)
  4. Clinical improvement per 6 Minute Walk Test (> 50 meters from baseline) and 5 meter walk test. (Appendix H)
  5. Mean ICU and total index procedure hospital length of stay

Additional Valve Performance Endpoints:

  1. Freedom from major mitral paravalvular leak
  2. Improvement in hemodynamic function: mean gradient
  3. Freedom from structural valve deterioration
  4. Total mitral regurgitation
02

Conditions studied

  • Mitral Valve Disease
03

In context

Lead sponsor

Mayra Guerrero is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria in Native Mitral Valve arm

All Candidates must meet the following criteria:

  1. Patient has severe calcific native mitral valve stenosis with mitral annular calcification with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2, or severe mitral regurgitation with severe mitral annular calcification and at least moderate mitral valve stenosis. Qualifying echo must be within 60 days of the date of the procedure.
  2. Patient is symptomatic from mitral valve disease, as demonstrated by reported Functional Class II or greater, or symptoms during stress test.
  3. The patient is at least 22 years old.
  4. The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
  5. The heart team agrees that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Specifically, the STS score is ≥15% or the probability of death or serious, irreversible morbidity is ≥ 50%. The surgeons' consult notes shall specify the medical or anatomic factors leading to that conclusion and include a printout of the calculation of the STS score to additionally identify the risks in the patient (some medical factors and definitions are provided below). At least one of the cardiac surgeon assessors must have physically evaluated the patient. All patients must be approved by the Patient Selection and Procedure Management Steering Committee (at least 2 member votes, one must be a cardiac surgeon).
  6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written as approved by the Institutional Review Board (IRB) of the respective clinical site.
  7. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.

Inclusion Criteria in Valve-in-Ring arm

All Candidates must meet the following criteria:

  1. Patient has a failing surgical ring in the mitral position with severe mitral regurgitation or stenosis (echocardiographically derived mitral valve area [MVA] of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
  2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test, or severe hemolytic anemia requiring blood transfusions and no other cause of hemolytic anemia is found after extensive work up.

Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above

Inclusion Criteria in Valve-in-Valve arm

All Candidates must meet the following criteria:

  1. Patient has a failing surgical bioprosthesis in the mitral position with severe mitral regurgitation or stenosis with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
  2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test.

Inclusion Criteria items #3 to 7 will be the same as in Native MV arm described above

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are present:

  1. Heart Team assessment of operability (the heart team considers the patient is a surgical candidate).
  2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
  3. Mitral annulus is not calcified (only applies to patients included in Native MV arm).
  4. Complex untreated coronary artery disease:

    1. Unprotected left main coronary artery
    2. Syntax score > 32 (in the absence of prior revascularization)
  5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not excluded.
  6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to procedure after a qualifying ECHO).
  7. Patients with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation.
  8. Leukopenia (WBC \< 3000 cell/mL), acute anemia ( \< 9 g/dL), Thrombocytopenia (Plt \< 50,000 cell/mL).
  9. Hypertrophic obstructive cardiomyopathy (HOCM).
  10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
  11. Need for emergency surgery for any reason.
  12. Severe ventricular dysfunction with \< 20%.
  13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  14. Active upper GI bleeding within 3 months (90 days) prior to procedure.
  15. A known or to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
  16. For patients enrolled in the Native MV arm: Native mitral annulus size \< 275 mm2 or > 740 mm2 as measured by CT scan.

    For patients in Valve-in-Ring arm: surgical ring with a true mean internal diameter ≤18 mm or ≥ 29 mm or an area \< 275 mm2 or > 740 mm2 as measured by CT scan. Caution recommended in:

    • Incomplete bands due to risk of paravalvular leak and risk of LVOT obstruction. Careful measurements by CT and CT-guided procedural planning is recommended.
    • Non-circular rigid or semi-flexible rings (e.g., D-shaped, saddle shaped, etc) due to risk of para-valvular leak and/or out of round or incomplete valve expansion.

    For patients in Valve-in-Valve arm: surgical bioprosthesis with a true internal diameter ≤18 mm or ≥ 29 mm

  17. Clinically (by neurologist) or neuroimaging confirmed stroke or (TIA) within 6 months (180 days) of the procedure.
  18. Estimated \< 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.
  19. Expectation that patient will not improve despite treatment of mitral stenosis
  20. Active bacterial endocarditis within 6 months (180 days) of procedure.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Native mitral valve with severe MAC

    Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.

    Device: Transcatheter Mitral Valve Replacement

  • Experimental
    Valve-in-Ring

    Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).

    Device: Transcatheter Mitral Valve Replacement

  • Experimental
    Valve-in-Valve

    Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).

    Device: Transcatheter Mitral Valve Replacement

Interventions

  • DeviceTranscatheter Mitral Valve Replacement

    Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.

06

What researchers measure

Primary outcomes

  1. Technical Success at Exit From the Cath Lab.

    Number of subject to achieve technical success (at exit from cath lab) is defined as: * Successful vascular delivery and retrieval of transcatheter valve delivery system * Deployment of single valve * Correct position of transcatheter valve * Adequate performance of prosthesis (MVA \> 1.5 cm2) without residual MR grade ≥2 (+) * No need for additional surgery or re-intervention * Patient leaves cath lab alive

    Time frame: 30 days

  2. Absence of MR Grade 2 (+) or Greater

    Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.

    Time frame: 30 days and 1 year

  3. Mitral Valve Gradient (MVG)

    MVG assessed by echocardiography measured in mmHg

    Time frame: 30 days and 1 year

Secondary outcomes

  1. Procedural Success

    Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.

    Time frame: 30 days

07

Results

Posted Aug 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
Started313030
Completed191929
Not completed12111
Withdrew: Death1071
Withdrew: Withdrawal by subject200
Withdrew: Lost to follow-up040

Outcome measures

PrimaryTechnical Success at Exit From the Cath Lab.

Number of subject to achieve technical success (at exit from cath lab) is defined as: * Successful vascular delivery and retrieval of transcatheter valve delivery system * Deployment of single valve * Correct position of transcatheter valve * Adequate performance of prosthesis (MVA \> 1.5 cm2) without residual MR grade ≥2 (+) * No need for additional surgery or re-intervention * Patient leaves cath lab alive

Time frame:
30 days
Reported as:
Count of participants · Participants
Technical Success at Exit From the Cath Lab.
ParticipantsNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
Technical Success at Exit From the Cath Lab.232030
PrimaryAbsence of MR Grade 2 (+) or Greater

Number of subjects to have absence of MR grade 2 (+) or greater assessed with echocardiography. MR severity grading system ranging from Grade 1=mild; Grade 4=severe.

Time frame:
30 days and 1 year
Reported as:
Count of participants · Participants
Absence of MR Grade 2 (+) or Greater
ParticipantsNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
30 days232829
1 year181929
PrimaryMitral Valve Gradient (MVG)

MVG assessed by echocardiography measured in mmHg

Time frame:
30 days and 1 year
Reported as:
Median · mmHg
Mitral Valve Gradient (MVG)
mmHgNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
30 days6.0 (5.2 to 7.8)7.6 (5.9 to 9.1)6.0 (4.7 to 7.3)
1 year6.1 (5.6 to 7.1)6.0 (4.7 to 7.3)6.6 (5.5 to 8.9)
SecondaryProcedural Success

Number of subject to have procedural success as defined as no device/procedure related SAE's including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.

Time frame:
30 days
Reported as:
Count of participants · Participants
Procedural Success
ParticipantsNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
Procedural Success162228

Adverse events

Collected over Adverse events were collected all subjects from baseline to end of study, approximately one year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Native Mitral Valve With Severe MAC10/31 (32.3%)18/31 (58.1%)17/31 (54.8%)
Valve-in-Ring7/30 (23.3%)13/30 (43.3%)12/30 (40%)
Valve-in-Valve1/30 (3.3%)8/30 (26.7%)6/30 (20%)
Most frequent serious events
Most frequent serious events
EventNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
New rehospitalization for heart failureCardiac disorders11/315/305/30
Acute Kidney InjuryRenal and urinary disorders5/314/300/30
Atrial fibrillationCardiac disorders5/311/300/30
Hemolytic anemiaBlood and lymphatic system disorders5/313/300/30
New permanent pacemaker requirementCardiac disorders5/310/301/30
Mitral valve reintervention after index procedureCardiac disorders4/313/300/30
StrokeNervous system disorders2/311/302/30
Vascular complicationsVascular disorders1/312/301/30
Valve thrombosisVascular disorders1/310/300/30
Most frequent other events
Most frequent other events
EventNative Mitral Valve With Severe MACValve-in-RingValve-in-Valve
Blood transfusionBlood and lymphatic system disorders17/3112/306/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Native Mitral Valve With Severe MACValve-in-RingValve-in-ValveTotal
Median74.5 (71.3 to 81.0)71.5 (67.0 to 76.8)77.5 (70.3 to 82.8)75.5 (67.75 to 82.25)
Sex: Female, Male
Sex: Female, Male(Participants)Native Mitral Valve With Severe MACValve-in-RingValve-in-ValveTotal
Female22111952
Male9191139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Native Mitral Valve With Severe MACValve-in-RingValve-in-ValveTotal
Hispanic or Latino1203
Not Hispanic or Latino30283088
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Native Mitral Valve With Severe MACValve-in-RingValve-in-ValveTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American0246
White31272583
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Native Mitral Valve With Severe MACValve-in-RingValve-in-ValveTotal
United States31303091
08

Study locations

15 sites
  • Banner University Medical Center
    Phoenix, Arizona 85006, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • MedStar Washington Medical Center
    Washington, District of Columbia 20010, United States
  • Piedmont HealtCare
    Atlanta, Georgia 30309, United States
  • Evanston Hospital / North Shore University HealthSystem
    Evanston, Illinois 60201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Hermann Texas Medical Center
    Houston, Texas 77030, United States
  • Intermountain Medical Center
    Murray, Utah 48107, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
09

References and documents

Publications

  • Guerrero M, Greenbaum A, O'Neill W. First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91. doi: 10.1002/ccd.25441. Epub 2014 Mar 14. PubMed 24532349 ↗
  • Sinning JM, Mellert F, Schiller W, Welz A, Nickenig G, Hammerstingl C. Transcatheter mitral valve replacement using a balloon-expandable prosthesis in a patient with calcified native mitral valve stenosis. Eur Heart J. 2013 Sep;34(33):2609. doi: 10.1093/eurheartj/eht254. Epub 2013 Jul 4. No abstract available. PubMed 23828829 ↗
  • Hasan R, Mahadevan VS, Schneider H, Clarke B. First in human transapical implantation of an inverted transcatheter aortic valve prosthesis to treat native mitral valve stenosis. Circulation. 2013 Aug 6;128(6):e74-6. doi: 10.1161/CIRCULATIONAHA.113.001466. No abstract available. PubMed 23918190 ↗
  • Fassa AA, Himbert D, Brochet E, Depoix JP, Cheong AP, Alkhoder S, Nataf P, Vahanian A. Transseptal transcatheter mitral valve implantation for severely calcified mitral stenosis. JACC Cardiovasc Interv. 2014 Jun;7(6):696-7. doi: 10.1016/j.jcin.2013.12.204. Epub 2014 May 14. No abstract available. PubMed 24835326 ↗
  • Ribeiro HB, Doyle D, Urena M, Allende R, Amat-Santos I, Pasian S, Bilodeau S, Mohammadi S, Paradis JM, DeLarochelliere R, Rodes-Cabau J, Dumont E. Transapical mitral implantation of a balloon-expandable valve in native mitral valve stenosis in a patient with previous transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014 Oct;7(10):e137-9. doi: 10.1016/j.jcin.2014.02.024. Epub 2014 Sep 17. No abstract available. PubMed 25240553 ↗
  • Ferrari E, Niclauss L, Locca D, Marcucci C. On-pump fibrillating heart mitral valve replacement with the SAPIEN XT transcatheter heart valve. Eur J Cardiothorac Surg. 2014 Apr;45(4):749-51. doi: 10.1093/ejcts/ezt364. Epub 2013 Jul 11. PubMed 23847181 ↗
  • Himbert D, Bouleti C, Iung B, Nejjari M, Brochet E, Depoix JP, Ghodbane W, Fassa AA, Nataf P, Vahanian A. Transcatheter valve replacement in patients with severe mitral valve disease and annular calcification. J Am Coll Cardiol. 2014 Dec 16;64(23):2557-8. doi: 10.1016/j.jacc.2014.09.047. No abstract available. PubMed 25500243 ↗
  • Guerrero M, Wang DD, Eleid MF, Pursnani A, Salinger M, Russell HM, Kodali SK, George I, Bapat VN, Dangas GD, Tang GHL, Inglesis I, Meduri CU, Palacios I, Reisman M, Whisenant BK, Jermihov A, Kaptzan T, Lewis BR, Tommaso C, Krause P, Thaden J, Oh JK, Douglas PS, Hahn RT, Leon MB, Rihal CS, Feldman T, O'Neill WW. Prospective Study of TMVR Using Balloon-Expandable Aortic Transcatheter Valves in MAC: MITRAL Trial 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):830-845. doi: 10.1016/j.jcin.2021.01.052. PubMed 33888229 ↗
  • Guerrero M, Wang DD, Pursnani A, Salinger M, Russell HM, Eleid M, Chakravarty T, Ng MH, Kodali SK, Meduri CU, Pershad A, Satler L, Waksman R, Palacios I, Smalling R, Reisman M, Gegenhuber M, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Douglas PS, Hahn RT, Kar S, Makkar R, Leon MB, Feldman T, Rihal C, O'Neill WW. Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings: MITRAL Trial Valve-in-Ring Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):846-858. doi: 10.1016/j.jcin.2021.01.051. PubMed 33888230 ↗
  • Guerrero M, Pursnani A, Narang A, Salinger M, Wang DD, Eleid M, Kodali SK, George I, Satler L, Waksman R, Meduri CU, Rajagopal V, Inglessis I, Palacios I, Reisman M, Eng MH, Russell HM, Pershad A, Fang K, Kar S, Makkar R, Saucedo J, Pearson P, Bokhary U, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Lang RM, Hahn RT, Leon MB, O'Neill WW, Feldman T, Rihal C. Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):859-872. doi: 10.1016/j.jcin.2021.02.027. PubMed 33888231 ↗
  • Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, Palacios I, Russell H, Makkar RR, Kar S, Satler LF, Rajagopal V, Dangas G, Tang GHL, McCabe JM, Whisenant BK, Fang K, Balan P, Smalling R, Kaptzan T, Lewis B, Douglas PS, Hahn RT, Thaden J, Oh JK, Leon M, O'Neill W, Rihal C. 5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results. JACC Cardiovasc Interv. 2023 Sep 25;16(18):2211-2227. doi: 10.1016/j.jcin.2023.06.041. PubMed 37758379 ↗
  • Sticchi A, Reineke D, Praz F, Windecker S. Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. JACC Cardiovasc Interv. 2021 Apr 26;14(8):873-878. doi: 10.1016/j.jcin.2021.02.034. No abstract available. PubMed 33888232 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Dec 2018, 46 months.

Results were first posted in Aug 2021, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2015
First posted
Feb 25, 2015
StartActual
Feb 25, 2015
Primary completionActual
Dec 2018
CompletionActual
Dec 2018
Results first posted
Aug 16, 2021
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02370511
Lead sponsor
Mayra Guerrero
Collaborators
Henry Ford Hospital
Responsible party
Mayra Guerrero (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Feb 25, 2015
Start date
Feb 25, 2015
Primary completion
Dec 2018
Completion
Dec 2018
Results posted
Aug 16, 2021
Last update
Oct 10, 2023

Study contacts

Mayra E. Guerrero, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion